The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model
Abstract
Aims: A routine secondary pharmacology screen indicated that reversibly binding oral P2Y 12 receptor antagonist ticagrelor could inhibit adenosine uptake in human erythrocytes, suggesting that ticagrelor may potentiate adenosine-mediated responses in vivo. The aim of this study was to further characterize the adenosine uptake inhibition in vitro and study possible physiological consequences of adenosine uptake inhibition by ticagrelor in an anesthetized dog model of coronary blood flow compared to dipyridamole. Methods and Results: We measured [2-3H]adenosine uptake in purified human erythrocytes and several cell lines in the presence of ticagrelor or the known uptake inhibitor dipyridamole as a comparator. Using an open-chest dog model (beagles), we measured the left anterior descending (LAD) coronary artery blood flow during reactive hyperemia after 1 minute occlusion or intracoronary infusion of adenosine before and after administration of vehicle, ticagrelor, or dipyridamole (each n = 8). Ticagrelor concentration-dependently inhibited adenosine uptake in human erythrocytes and in cell lines of rat, canine, or human origin. In the dog model, ticagrelor and dipyridamole dose-dependently augmented reactive hyperemia after LAD occlusion, as assessed by percentage repayment of flow debt relative to control (both Ps < .05). Ticagrelor and dipyridamole also dose-dependently augmented intracoronary adenosine-induced increases in LAD blood flow relative to control (both Ps < .05). Conclusion: Ticagrelor inhibits adenosine uptake in vitro and subsequently augments cardiac blood flow in a canine model of reactive hypoxia- or adenosine-induced blood flow increases. These findings suggest that ticagrelor may have additional benefits in patients with acute coronary syndrome beyond inhibition of platelet aggregation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790 · cited 1×
“Dyspnea is unlikely to be associated with P2Y12 blockade itself, since increased blockade of the receptor by prasugrel did not seem to result in increased reporting of dyspnea.(8,33) Dyspnea is recognized as a side effect of intravenous adenosine administration in humans.”
BackgroundAspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
Sacco, R. L., Diener, H.-C., Yusuf, S., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805002 · Cited by 961
Cited by
Purinergic Signaling during Inflammation
Eltzschig, H. K., Sitkovsky, M. V., & Robson, S. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1205750 · Cited by 706
Purinergic Signaling during Inflammation
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1300259 · Cited by 608
Adenosine-Mediated Effects of Ticagrelor
Cattaneo, M., Schulz, R., & Nylander, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.031 · Cited by 312
Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome
Bonello, L., Laine, M., Kipson, N., Mancini, J., Helal, O., Fromonot, J., Gariboldi, V., Condo, J., Thuny, F., Frere, C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.067 · Cited by 283
Adenosine and Adenosine Receptor-Mediated Action in Coronary Microcirculation
Zhang, Y., Wernly, B., Cao, X., Mustafa, S. J., Tang, Y., & Zhou, Z. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00859-7 · Cited by 71
Metadata
- Authors
- van Giezen, J. J. J., Sidaway, J., Glaves, P., Kirk, I., & Björkman, J.-A.
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2011-06-22
- Volume
- 17
- Issue
- 2
- Pages
- 164-172
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W1970487416
- Cited by
- 198
- References
- 3
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model. https://app.cochat.ai/papers/10.1177/1074248411410883
- The paper
- van Giezen, J. J. J., Sidaway, J., Glaves, P., Kirk, I., & Björkman, J.-A. (2012). Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248411410883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.